Related Experiment Video
Updated: Jun 7, 2026
08:18
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
Published on: December 26, 2015
Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis
1Department of Neurology, Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy. comi.giancarlo@hsr.it
Summary
Cognitive dysfunction is common in multiple sclerosis (MS), impacting life quality. While immunomodulatory treatments show potential benefits for MS-related cognitive issues, study results require cautious interpretation due to methodological concerns.
Area of Science:
- Neuroimmunology
- Cognitive Neuroscience
- Clinical Neurology
Background:
- Cognitive dysfunctions are prevalent in multiple sclerosis (MS).
- These dysfunctions negatively affect patients' employment and quality of life.
- The pathophysiology is multifactorial, involving lesions, inflammation, and brain matter changes.
Purpose of the Study:
- To explore the role of immunomodulatory treatments in managing MS-related cognitive dysfunction.
- To evaluate the efficacy of available treatments based on clinical trial data.
Main Methods:
- Analysis of pivotal phase III clinical trials for immunomodulatory treatments in MS.
- Review of post-marketing studies assessing treatment benefits.
- Critical evaluation of study methodologies.
Main Results:
- Immunomodulatory treatments may positively influence some pathogenetic factors of MS cognitive dysfunction.
- Phase III trials and post-marketing studies suggest potential benefits.
- Methodological limitations in existing studies necessitate cautious interpretation of results.
Conclusions:
- Immunomodulatory therapies offer a potential avenue for addressing cognitive dysfunction in MS.
- Further high-quality research is needed to confirm treatment efficacy.
- Careful consideration of study limitations is crucial when assessing treatment outcomes.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...